Clinical Research, Pharma & Healthcare FinancingExicure Plans New Clinical Trial for Acute Myeloid LeukemiaBusiness WireApril 15, 2025April 15, 2025 by Business WireApril 15, 2025April 15, 202507 Exicure, Inc. (Nasdaq: XCUR) today shared updates on its lead asset, GPC-100 (burixafor), a small molecule CXCR4 inhibitor. Exicure, Inc. (“Exicure”) is planning for a...
